Zurich, Switzerland, 15th October 2015 – Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products, today announces that positive pre-clinical data assessing the potential of KUR-115 as a lumber interbody spinal fusion treatment will be presented today